Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Second-Line”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT02154737
What this trial is testing

Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Tony Reid, M.D., Ph.D. 24
Testing effectiveness (Phase 2)UnknownNCT05982834
What this trial is testing

Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC

Who this might be right for
HER2-positive Gastric CancerImmunotherapy
Fudan University 43
Testing effectiveness (Phase 2)Study completedNCT00565981
What this trial is testing

A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response

Who this might be right for
B-cell Chronic Lymphocytic Leukemia
Arbeitsgemeinschaft medikamentoese Tumortherapie 10
Testing effectiveness (Phase 2)Looking for participantsNCT03364530
What this trial is testing

Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma

Who this might be right for
Cholangiocarcinoma Non-resectableNon-metastatic
University Hospital, Montpellier 40
Early research (Phase 1)Study completedNCT02151864
What this trial is testing

LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis

Who this might be right for
Hepatocellular CarcinomaCirrhosis
Jason K. Sicklick, M.D. 9
Testing effectiveness (Phase 2)Study completedNCT02089763
What this trial is testing

Efficacy Study of Pegylated Recombinant Human Arginase 1 as a Second-line Therapy in Patients With Advanced Liver Cancer

Who this might be right for
Hepatocellular Carcinoma
Bio-Cancer Treatment International Limited 27
Not applicableStudy completedNCT02246725
What this trial is testing

Observational Study of Early Contact With Palliative Care Unit for Patients Receiving First Line Palliative Chemotherapy With Cancer in Upper Gastrointestinal Canal, or Second Line Palliative Chemotherapy in Patients With Colorectal Cancer - an Open, Randomised Investigator Initiated Trial.

Who this might be right for
Tumor in Upper Gastrointestinal Canal or Patients With Colorectal Cancer
Lund University Hospital 108
Testing effectiveness (Phase 2)Study completedNCT01788982
What this trial is testing

Nintedanib(BIBF1120) in Thyroid Cancer

Who this might be right for
Medullary Thyroid Cancer (MTC)Differentiated Thyroid Cancer (DTC)
European Organisation for Research and Treatment of Cancer - EORTC 100
Testing effectiveness (Phase 2)Ended earlyNCT01696890
What this trial is testing

Integration of Follow-up by First and Second Line Practitioners by Telemonitoring in Heart Failure.

Who this might be right for
Chronic Heart Failure
Jessa Hospital 50
Not applicableUnknownNCT03766490
What this trial is testing

Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung
The First Affiliated Hospital of Soochow University 66
Testing effectiveness (Phase 2)Study completedNCT04350190
What this trial is testing

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Who this might be right for
Nasopharyngeal Carcinoma
Wei Jiang 25
Large-scale testing (Phase 3)Study completedNCT01183858
What this trial is testing

Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 315
Testing effectiveness (Phase 2)UnknownNCT03144843
What this trial is testing

Apatinib Combined With Paclitaxol as Second Line Therapy for Advanced Gastric Cancer.

Who this might be right for
Gastric Cancer
Sun Yat-sen University 110
Post-approval studies (Phase 4)UnknownNCT01537055
What this trial is testing

Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy

Who this might be right for
Eradication Rate for Helicobacter
National Taiwan University Hospital 600
Not applicableStudy completedNCT00050089
What this trial is testing

CSP #512 - Options in Management With Anti-Retrovirals

Who this might be right for
AIDSHIV Infections
US Department of Veterans Affairs 368
Testing effectiveness (Phase 2)Active Not RecruitingNCT07143604
What this trial is testing

Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2

Who this might be right for
Gastric CancerGastroesophageal Junction Cancer
AstraZeneca 33
Large-scale testing (Phase 3)Study completedNCT01767155
What this trial is testing

Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer

Who this might be right for
Endometrial Cancer
AEterna Zentaris 511
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06339216
What this trial is testing

A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer.

Who this might be right for
Gastric Cancer
Chinese PLA General Hospital 30
Large-scale testing (Phase 3)Study completedNCT01160211
What this trial is testing

Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 369
Testing effectiveness (Phase 2)Active Not RecruitingNCT04284787
What this trial is testing

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+1 more
National Cancer Institute (NCI)
Next Page
60